Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial

作者
Hyatt Balke‐Want,Philipp Gödel,Christoph Schmid,Francis Ayuketang Ayuk,Birte Friedrichs,Pearl van Heteren,Silke Holtkamp,Gregor Zadoyan,Corinne Brillant,Joana Costa,Linda Hanssens,Tatjana Holzer,Christian Wöhle,Stefanie Biedermann,Iris Bürger,Rimas J. Orentas,Toon Overstijns,Christof Scheid,Udo Holtick,Stefan Miltenyi
出处
期刊:Blood Advances [Elsevier BV]
卷期号:10 (7): 2395-2405 被引量:6
标识
DOI:10.1182/bloodadvances.2025018073
摘要

ABSTRACT: Emerging long-term data indicate relapse rates of >50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phase 1 clinical trial of zamtocabtagene autoleucel (zamto-cel), a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy. Two predefined dose levels (dose level 1 [DL1], 1 × 106 and DL2, 2.5 × 106 CAR+ T cells per kg bodyweight) were applied. The primary end point (EP) was the maximum tolerated dose (MTD). Secondary EPs included adverse events, best overall response (BOR), and biomarker assessments. A total of 12 patients, 6 patients per DL, were treated. No dose-limiting toxicity and no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome of grade ≥3 were observed. Thus, MTD was not reached. The BOR by investigator assessment was 75%, with 5 of 12 patients (42%) achieving complete remission (CR) until month 12 with no relapse in clinical evaluation up to 5 years after infusion. CR was associated with a higher mean maximum observed concentration of zamto-cel and detection of zamto-cel beyond month 6. Additional product characterization revealed increased expression of CD27 and CD127 along with increased expansion of CAR+ central memory T cells in patients with CR, facilitating persistence and improved outcomes in R/R B-NHL treated with zamto-cel. Based on the promising risk-to-benefit ratio, evaluation of zamto-cel at DL2 is ongoing in pivotal phase 2 clinical trials for patients with R/R aggressive B-NHL. This trial was registered at www.ClinicalTrials.gov as NCT03870945.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
火星上的母鸡完成签到,获得积分10
刚刚
小白完成签到,获得积分10
1秒前
优雅醉蓝发布了新的文献求助30
1秒前
想要的都有完成签到 ,获得积分10
1秒前
May完成签到,获得积分10
1秒前
1秒前
震动的念波完成签到 ,获得积分10
2秒前
2秒前
Canon不肉发布了新的文献求助10
2秒前
niubidema完成签到,获得积分10
2秒前
2秒前
华仔的应助被111采纳,获得10
2秒前
Maverick完成签到,获得积分10
2秒前
QDU的应助被YPHCC采纳,获得10
3秒前
gg完成签到,获得积分10
3秒前
cdercder的应助被元谷雪采纳,获得10
3秒前
IRONFOREST完成签到 ,获得积分10
3秒前
YanJinyu完成签到,获得积分10
4秒前
adai007发布了新的文献求助10
4秒前
天天向上的应助被mwx采纳,获得10
4秒前
清爽老九发布了新的文献求助30
4秒前
lc完成签到,获得积分10
4秒前
天空完成签到,获得积分10
5秒前
自然的诗翠完成签到,获得积分10
5秒前
瀛洲晚风发布了新的文献求助100
5秒前
儒雅水池完成签到,获得积分10
6秒前
佳jia完成签到 ,获得积分10
6秒前
甜蜜的白猫完成签到,获得积分10
7秒前
7秒前
吴青完成签到,获得积分10
7秒前
7秒前
整齐的飞兰完成签到 ,获得积分10
7秒前
超人研究生完成签到,获得积分10
7秒前
积极的皮皮虾完成签到 ,获得积分10
8秒前
8秒前
传奇3的应助被小太阳采纳,获得10
9秒前
9秒前
王晓阳完成签到 ,获得积分10
9秒前
10秒前
Whisper完成签到 ,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105